Generic Aklief Availability
Last updated on Sep 11, 2024.
Aklief is a brand name of trifarotene topical, approved by the FDA in the following formulation(s):
AKLIEF (trifarotene - cream;topical)
-
Manufacturer: GALDERMA LABS LP
Approval date: October 4, 2019
Strength(s): 0.005% [RLD]
Has a generic version of Aklief been approved?
No. There is currently no therapeutically equivalent version of Aklief available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aklief. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 7,807,708
Patent expiration dates:
- July 19, 2031✓✓
- July 19, 2031
-
Ligands that modulate RAR receptors
Patent 8,227,507
Issued: July 24, 2012
Inventor(s): Biadatti Thibaud & Dumais Laurence & Soulet Catherine & Talano Sandrine & Daver Sebastien
Assignee(s): Galderma Research & DevelopmentNovel ligand compounds having the general formula (I):
Patent expiration dates:
- December 21, 2025✓
- December 21, 2025
-
Ligands that modulate RAR receptors
Patent 8,470,871
Issued: June 25, 2013
Inventor(s): Biadatti Thibaud & Dumais Laurence & Soulet Catherine & Talano Sandrine & Daver Sebastien
Assignee(s): Galderma Research & DevelopmentNovel ligand compounds having the general formula (I):
Patent expiration dates:
- December 21, 2025✓
- December 21, 2025
-
Topical compositions containing a retinoid of the oil-in-water emulsion type
Patent 9,084,778
Issued: July 21, 2015
Inventor(s): Duprat Agnes & Mallard Claire
Assignee(s): GALDERMA RESEARCH & DEVELOPMENTA composition in the form of an oil in water emulsion, preferably without emulsifier, is described. The composition can include, in a physiologically acceptable environment, at least one new retinoid. Also described, is the method of preparing the composition and its use in cosmetics and dermatology.
Patent expiration dates:
- May 30, 2033✓✓
- May 30, 2033
-
Topical compositions in the form of a gel containing a particular solubilized retinoid
Patent 9,498,465
Issued: November 22, 2016
Inventor(s): Duprat Agnès & Mallard Claire
Assignee(s): GALDERMA RESEARCH & DEVELOPMENTA composition in the form of a gel, preferably hydroglycolic, is described. The composition can include in a physiologically acceptable medium, at least one particular retinoid. Also described, is a method for the preparation thereof and the cosmetic and dermatological use of the same.
Patent expiration dates:
- May 30, 2033✓✓
- May 30, 2033
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- October 4, 2024 - NEW CHEMICAL ENTITY
More about Aklief (trifarotene topical)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: topical acne agents
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.